ArticleInternational journal of hematology2017
Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.
Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Repurposing resveratrol for redox-mediated inhibition of MTH1 in breast cancer.Scientific reports · 2025Article
- Clinical Significance of NUDT1 (MTH1) Across Cancer Types.International journal of molecular sciences · 2025Review
- MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.Cancer research · 2021Article
- Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.International journal of molecular sciences · 2020Article
- The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.Molecular cancer therapeutics · 2020Article
- Potent and specific MTH1 inhibitors targeting gastric cancer.Cell death & disease · 2019Article
- The role of miR-485-5p/NUDT1 axis in gastric cancer.Cancer cell international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human MutT homologue 1 (MTH1) is a human 8-oxo-dGTPase that eradicates oxidized bases in the nucleotide pool and DNA. MTH1 is critical for RAS-transformed cancer cell survival, whereas it is dispensable in normal cells and tissues. Here, we determined the expression of MTH1 in multiple myeloma (MM) cell lines and MM patients' CD138 (+) cells and analyzed its potential clinical significance. We detected overexpression of MTH1 mRNA in three cell lines (RPMI 8226, U266, and H929). MTH1 mRNA expression of RPMI8226 was higher than that of U266 and H929. In 59 MM patients, overexpression of MTH1 mRNA was detected in 27 cases (45.7%). MTH1 mRNA expression was significantly higher in ISS III stage (P < 0.001) and refractory relapse patients (P < 0.05). MTH1 mRNA expression in patients achieving less than partial response (PR) was significantly higher than in those achieving PR and better in newly diagnosed MM (P = 0.04). In conclusion, higher MTH1 may be associated with later disease stage and advanced disease progression. MTH1 mRNA overexpression is also correlated poor efficacy of bortezomib in newly diagnosed MM patients.
Indexed as
Identifiers
27848179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.